The Weight of Cardiovascular Disease

Description

The purpose of this study is to evaluate the impact of a cardiometabolic clinic on percent body weight loss, body mass index (BMI), and visceral adiposity distribution in obese adults with cardiovascular disease (CVD) at 12 months.

Conditions

Cardiovascular Diseases, Obesity

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to evaluate the impact of a cardiometabolic clinic on percent body weight loss, body mass index (BMI), and visceral adiposity distribution in obese adults with cardiovascular disease (CVD) at 12 months.

The Weight of Cardiovascular Disease: A Prospective Pilot Study of Obese Adults With Cardiovascular Disease Evaluated in a Novel Cardiometabolic Clinic

The Weight of Cardiovascular Disease

Condition
Cardiovascular Diseases
Intervention / Treatment

-

Contacts and Locations

Rochester

Mayo Clinic in Rochester, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * BMI ≥30 kg/m2
  • * At least one of the following CVD: atrial fibrillation (AF), coronary artery disease (CAD), HFpEF (heart failure with preserved ejection fraction), HFrEF (heart failure with reduced ejection fraction), ACHD (adult congenital heart disease), or valvular heart disease
  • * Patients evaluated in the Cardiometabolic clinic
  • * Willingness to complete questionnaires/surveys
  • * Ability to complete monthly self-assessments at home
  • * BMI \<30 kg/m2
  • * Pregnancy or lactating women
  • * Hemodynamically unstable CVD
  • * Active malignancy
  • * Autoimmune or systemic inflammatory diseases
  • * Severe renal or hepatic failure
  • * Being considered unsafe to participate as determined by the study physician
  • * Taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic medications, or other medications as determined by the study NP or physician
  • * Patients with active psychosis, mania, or substance use disorders

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Kyla Lara-Breitinger, M.D., PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2025-09